» Articles » PMID: 21234417

Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes

Overview
Publisher Wiley
Date 2011 Jan 15
PMID 21234417
Citations 93
Authors
Affiliations
Soon will be listed here.
Abstract

Lipid rafts are membrane microdomains, enriched in cholesterol and sphingolipids, into which specific subsets of proteins and lipids partition, creating cell-signalling platforms that are vital for neuronal functions. Lipid rafts play at least three crucial roles in Alzheimer's Disease (AD), namely, in promoting the generation of the amyloid-β (Aβ) peptide, facilitating its aggregation upon neuronal membranes to form toxic oligomers and hosting specific neuronal receptors through which the AD-related neurotoxicity and memory impairments of the Aβ oligomers are transduced. Recent evidence suggests that Aβ oligomers may exert their deleterious effects through binding to, and causing the aberrant clustering of, lipid raft proteins including the cellular prion protein and glutamate receptors. The formation of these pathogenic lipid raft-based platforms may be critical for the toxic signalling mechanisms that underlie synaptic dysfunction and neuropathology in AD.

Citing Articles

Investigating the Impact of NMDA Receptor Organization and Biological Sex in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Hadzibegovic S, Bontempi B, Nicole O Int J Mol Sci. 2025; 26(4).

PMID: 40004200 PMC: 11855313. DOI: 10.3390/ijms26041737.


Inhibition of Aβ Aggregation by Cholesterol-End-Modified PEG Vesicles and Micelles.

Watanabe S, Ueda M, Asayama S Pharmaceutics. 2025; 17(1).

PMID: 39861653 PMC: 11769297. DOI: 10.3390/pharmaceutics17010001.


Multiomics of Aging and Aging-Related Diseases.

Kiseleva O, Arzumanian V, Ikhalaynen Y, Kurbatov I, Kryukova P, Poverennaya E Int J Mol Sci. 2025; 25(24.

PMID: 39769433 PMC: 11677528. DOI: 10.3390/ijms252413671.


The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer's Disease: A Possible Target for the Disease Treatment.

Testa G, Giannelli S, Staurenghi E, Cecci R, Floro L, Gamba P Int J Mol Sci. 2025; 25(24.

PMID: 39769398 PMC: 11727734. DOI: 10.3390/ijms252413637.


Insulin resistance as the molecular link between diabetes and Alzheimer's disease.

Abdalla M World J Diabetes. 2024; 15(7):1430-1447.

PMID: 39099819 PMC: 11292327. DOI: 10.4239/wjd.v15.i7.1430.


References
1.
Zandi P, Sparks D, Khachaturian A, Tschanz J, Norton M, Steinberg M . Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005; 62(2):217-24. DOI: 10.1001/archpsyc.62.2.217. View

2.
Kawarabayashi T, Shoji M, Younkin L, Wen-Lang L, Dickson D, Murakami T . Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2004; 24(15):3801-9. PMC: 6729359. DOI: 10.1523/JNEUROSCI.5543-03.2004. View

3.
Umeda T, Mori H, Zheng H, Tomiyama T . Regulation of cholesterol efflux by amyloid beta secretion. J Neurosci Res. 2010; 88(9):1985-94. DOI: 10.1002/jnr.22360. View

4.
Malenka R, Bear M . LTP and LTD: an embarrassment of riches. Neuron. 2004; 44(1):5-21. DOI: 10.1016/j.neuron.2004.09.012. View

5.
Sparks D, Sabbagh M, Connor D, Lopez J, Launer L, Browne P . Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005; 62(5):753-7. DOI: 10.1001/archneur.62.5.753. View